oms906
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 9, 2022 (NCT05889299)
Timeline
Indications
Mechanism of action
- masp3INHIBITOR
masp3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06209736 | Phase 2 | Mar 1, 2024 | Omeros Corporation |
| NCT06298955 | Phase 2 | Feb 19, 2024 | Omeros Corporation |
| NCT05972967 | Phase 2 | Mar 27, 2023 | Omeros Corporation |
| NCT05889299 | Phase 1 | Dec 9, 2022 | Omeros Corporation |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Omeros Corporation | For profit | 4 | 4 | 2 | 2022 |
1 organizations
Page 1 / 1